Archives: 2022-08-09

PIER MARIA FORNASARI
2022-08-09

Higher doses of CAR T cell therapy associate with improved outcomes in young patients with B-ALL : a report from the pediatric real-world CAR consortium

Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.   Since its approval as the first

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-08-08

Pfizer-BioNTech Vaccine Targeting Fast-Spreading Omicron BA.1 and BA.4/5 will be delivered as soon as October 2022

Pfizer and BioNTech will begin trials of their updated mRNA Covid-19 vaccine designed to protect against the newer BA.4 and BA.5 sub-variants of the coronavirus latest this month, BioNTech announced on Monday, joining other vaccine makers like Moderna who are trying to create updated shots targeting the faster spreading and immune evasive variants. The trial

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-08-07

Dysregulation of the kallikrein-kinin system and neutrophils role in bronchoalveolar lavage fluid of patients with severe COVID-19

Results published by University of Leuven researchers in eBioMedicine Markers of inflammation and coagulation are predictors for clinical outcomes in patients with COVID-19. Binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to the angiotensin converting enzyme 2 receptor, which is involved in kinin breakdown, could interfere with the kallikrein-kinin pathway. SARS-CoV-2 induced dysregulation

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-08-06

12,7% COVID-19 patients develop long COVID symptoms: results of a large Dutch study

One in eight adults (12.7%) who are infected with SARS-CoV-2 experience long term symptoms due to COVID-19, suggests a large Dutch study published in The Lancet. The study provides one of the first comparisons of long-term symptoms after SARS-CoV-2 infection (often called ‘long COVID’) with symptoms in an uninfected population, as well as measuring symptoms in

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-08-06

St. Jude Researchers improved CAR T-cell therapy for T-cell acute lymphoblastic leukemia

Scientists at St. Jude Children’s Research Hospital developed a simple method to select for more effective cancer-destroying CAR T cells for patients with relapsed T-ALL. Scientists at St. Jude Children’s Research Hospital are improving chimeric antigen receptor (CAR) T-cell therapy. Their new simplified approach selected for an advantageous T-cell type and showed promise in the lab against relapsed T-cell

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2022-08-03

Gene Therapy Approach Shows Promise in Treating ALS

In rodent models, introduced neuroprotective protein slowed disease progression and increased life span Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the progressive loss of motor neurons in the brain and spinal cord responsible for voluntary movements and muscle control. In a new study, published July 11, 2022 in the journal Theranostics, researchers at

Read More

No Comments InGENE THERAPY RARE DISEASES